2 research outputs found
Intravenska trombolitična terapija pomoću rt-PA u pedeset šestoro bolesnika s ishemijskim moždanim udarom - prospektivna studija praćenja
Get PDFIntravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) has recently reached the goal of becoming standard therapy in the acute stage of ischemic stroke in many countries. This appears to be one of the first pilot study reports from the region of Central and Eastern Europe. From January 1998 till October 2002, 56 consecutive patients underwent rt-PA thrombolysis at the University Department of Neurology, Nitra University Hospital, Slovakia. Selection criteria for the study were based on the NINDS study, with emphasis on the 3-hour therapeutic window. The mean baseline NIHSS wasR14.5, mean therapeutic interval 167 minutes, and mean intravenous rt-PA dose 0.7 mg/kg body weight. AtR3 months, mRS 0-1 was recorded in 33.9%, mRS 2-3 in 37.5%, and mRS 4-5 in 16.1% of study patients. Clinically relevant mRS 0-2 was achieved in 44.6% of study patients. The mortality was 12.5%. The rate of symptomatic and fatal intracerebral hemorrhage was 8.9% and 5.3%, respectively. Asymptomatic hemorrhagic transformation of a benign course was relatively frequently recorded (19.6%). Results of the study showed our stroke patients treated with intravenous rt-PA to have a favorable prognosis, and were comparable with those reported from the NINDS study and recent clinical studies.Intravenska tromboliza pomoću rekombinantnog aktivatora tkivnog plazminogena (rt-PA) odnedavno je postigla svoj cilj i u mnogim zemljama postala standardnim načinom liječenja akutnog stadija ishemijskog moždanog udara. Ovo je, čini se, jedno od prvih objavljenih probnih ispitivanja u području središnje i istočne Europe. U razdoblju od siječnja 1998. do listopada 2002. godine je na Klinici za neurologiju Sveučilišne bolnice Nitra iz Nitre, Slovačka, 56 uzastopnih bolesnika podvrgnuto trombolizi. Kriteriji za odabir bolesnika zasnivali su se na studiji NINDS, poglavito terapijski prozor od 3 sata. Postignuli smo prosječan bazalni NIHSS od 14,5, prosječan terapijski interval bio je 167 minuta, a prosječena doza intravenskog rt-PA bila je 0,7 mg/kg tjelesne težine. Nakon 3 mjeseca mRS 0-1 dostignulo je 33,9%, mRS 2-3 37,5%, te mRS 4-5 16,1% bolesnika. Klinički važan mRS 0-2 postiglo je 44,6% bolesnika. Smrtnost je bila 12,5%. Stopa simptomatskog unutarmoždanog krvarenja bila je 8,9%, a fatalnog 5,3%. Asimptomatska hemoragijska transformacija bila je relativno česta, tj. u 19,6% bolesnika s benignim tijekom. Zaključeno je kako bolesnici s moždanim udarom koji se liječe intravenskom rt-PA trombolizom u našoj bolnici imaju dobru prognozu, usporedivu s rezultatima studije NINDS i drugim novijim kliničkim studijama
Intravenska trombolitična terapija pomoću rt-PA u pedeset šestoro bolesnika s ishemijskim moždanim udarom - prospektivna studija praćenja
Get PDFIntravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) has recently reached the goal of becoming standard therapy in the acute stage of ischemic stroke in many countries. This appears to be one of the first pilot study reports from the region of Central and Eastern Europe. From January 1998 till October 2002, 56 consecutive patients underwent rt-PA thrombolysis at the University Department of Neurology, Nitra University Hospital, Slovakia. Selection criteria for the study were based on the NINDS study, with emphasis on the 3-hour therapeutic window. The mean baseline NIHSS wasR14.5, mean therapeutic interval 167 minutes, and mean intravenous rt-PA dose 0.7 mg/kg body weight. AtR3 months, mRS 0-1 was recorded in 33.9%, mRS 2-3 in 37.5%, and mRS 4-5 in 16.1% of study patients. Clinically relevant mRS 0-2 was achieved in 44.6% of study patients. The mortality was 12.5%. The rate of symptomatic and fatal intracerebral hemorrhage was 8.9% and 5.3%, respectively. Asymptomatic hemorrhagic transformation of a benign course was relatively frequently recorded (19.6%). Results of the study showed our stroke patients treated with intravenous rt-PA to have a favorable prognosis, and were comparable with those reported from the NINDS study and recent clinical studies.Intravenska tromboliza pomoću rekombinantnog aktivatora tkivnog plazminogena (rt-PA) odnedavno je postigla svoj cilj i u mnogim zemljama postala standardnim načinom liječenja akutnog stadija ishemijskog moždanog udara. Ovo je, čini se, jedno od prvih objavljenih probnih ispitivanja u području središnje i istočne Europe. U razdoblju od siječnja 1998. do listopada 2002. godine je na Klinici za neurologiju Sveučilišne bolnice Nitra iz Nitre, Slovačka, 56 uzastopnih bolesnika podvrgnuto trombolizi. Kriteriji za odabir bolesnika zasnivali su se na studiji NINDS, poglavito terapijski prozor od 3 sata. Postignuli smo prosječan bazalni NIHSS od 14,5, prosječan terapijski interval bio je 167 minuta, a prosječena doza intravenskog rt-PA bila je 0,7 mg/kg tjelesne težine. Nakon 3 mjeseca mRS 0-1 dostignulo je 33,9%, mRS 2-3 37,5%, te mRS 4-5 16,1% bolesnika. Klinički važan mRS 0-2 postiglo je 44,6% bolesnika. Smrtnost je bila 12,5%. Stopa simptomatskog unutarmoždanog krvarenja bila je 8,9%, a fatalnog 5,3%. Asimptomatska hemoragijska transformacija bila je relativno česta, tj. u 19,6% bolesnika s benignim tijekom. Zaključeno je kako bolesnici s moždanim udarom koji se liječe intravenskom rt-PA trombolizom u našoj bolnici imaju dobru prognozu, usporedivu s rezultatima studije NINDS i drugim novijim kliničkim studijama
